biotech equivalent to microsoft

At present PYC is heading in five unique ground breaking directions.

They are:

.Roche deal - transporting of macro-molecules into cells with the aid of a peptide carrier (cutting-edge).

.Medimmune deal- finding peptide antibiotics to counter the worldwide rise of antibiotic resistent hospital acquired infections (superbugs).

.Pfizer deal - next generation vaccine program

.MRC Hutchison Research Centre (Cambridge University) collaboration - development of a revolutionary approach to cancer research. 'Protein Interference', would have wide application in the identification and validation of new drug targets.

.CD40L internal program - next generation auto-immune disease treatment. The move from injectable meds to oral or nasel administration.

.Sonic Hedge-hog internal program - at the cutting-edge of cancer research.

My pick of the five, is the collaboration with MRC Hutchison (Cambridge university). This research should lead to a new way of thinking worldwide when it comes to cancer research. It will open the gate and who knows where the horse will bolt for cancer research and PYC.
At present there are intense ongoing discussions with the MRC Hutchison Institute concerning growth of the collaboration and the exciting commercial opportunities.

What value should be placed on PYC?
What should PYCs sp be sitting on to reflect it's potential?
Should PYC forget about an exit and build a biotech equivalent to microsoft?
Is now the time to stop selling PYC and watch the sp rise?

Cheers ST
DYOR and be amazed